Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 2/2013

01.06.2013 | Original Article

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

verfasst von: Chulhan Kim, Hyun Hoon Chung, So Won Oh, Keon Wook Kang, June-Key Chung, Dong Soo Lee

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Borderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs.

Methods

Among 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUVmax), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively.

Results

The BOT group (n = 7) was comprised of five mucinous and two serous tumors, and the MOT group (n = 6) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUVmax of the BOT group was significantly lower than that of the MOT group (2.9 ± 1.5 vs. 6.6 ± 2.9, p = 0.0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUVmax of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3 % and specificity of 85.7, and the area under curve of 0.893 (p = 0.0001, 95 % CI: 0.601∼0.993).

Conclusions

We demonstrated that SUVmax could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors.
Literatur
1.
Zurück zum Zitat deSouza NM, O’Neill R, McIndoe GA, Dina R, Soutter WP. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. Am J Roentgenol. 2005;184:999–1003.CrossRef deSouza NM, O’Neill R, McIndoe GA, Dina R, Soutter WP. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. Am J Roentgenol. 2005;184:999–1003.CrossRef
2.
Zurück zum Zitat Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005;97:780–3.PubMedCrossRef Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005;97:780–3.PubMedCrossRef
3.
Zurück zum Zitat Manchul LA, Simm J, Levin W, Fyles AW, Dembo AJ, Pringle JF, et al. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys. 1992;22:867–74.PubMedCrossRef Manchul LA, Simm J, Levin W, Fyles AW, Dembo AJ, Pringle JF, et al. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys. 1992;22:867–74.PubMedCrossRef
4.
Zurück zum Zitat Cadron I, Leunen K, Gorp TV, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25:2928–37.PubMedCrossRef Cadron I, Leunen K, Gorp TV, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25:2928–37.PubMedCrossRef
5.
Zurück zum Zitat Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl. 3:274–81.PubMedCrossRef Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl. 3:274–81.PubMedCrossRef
6.
Zurück zum Zitat Jacob I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12.CrossRef Jacob I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12.CrossRef
7.
Zurück zum Zitat Makhija S, Howden N, Edwards R, Kelley R, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53–8.PubMedCrossRef Makhija S, Howden N, Edwards R, Kelley R, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53–8.PubMedCrossRef
8.
Zurück zum Zitat Chung HH, Kang WJ, Kim JW, Park N-H, Song Y-S, Chung J-K, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480–6.PubMedCrossRef Chung HH, Kang WJ, Kim JW, Park N-H, Song Y-S, Chung J-K, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480–6.PubMedCrossRef
9.
Zurück zum Zitat Jung DC, Choi HJ, Ju W, Kim SC, Choi K-G. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumours. Int J Gynecol Cancer. 2008;18:637–41.PubMedCrossRef Jung DC, Choi HJ, Ju W, Kim SC, Choi K-G. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumours. Int J Gynecol Cancer. 2008;18:637–41.PubMedCrossRef
10.
Zurück zum Zitat Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–63.PubMedCrossRef Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–63.PubMedCrossRef
11.
Zurück zum Zitat Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.PubMedCrossRef Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.PubMedCrossRef
12.
Zurück zum Zitat Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83(1):3440.CrossRef Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83(1):3440.CrossRef
13.
Zurück zum Zitat Takemori M, Nishimura R, Hasegawa K. Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors. Acta Obstet Gynecol Scand. 2002;81:157–61.PubMedCrossRef Takemori M, Nishimura R, Hasegawa K. Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors. Acta Obstet Gynecol Scand. 2002;81:157–61.PubMedCrossRef
14.
Zurück zum Zitat Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging. 2002;29:797–803.PubMedCrossRef Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging. 2002;29:797–803.PubMedCrossRef
15.
Zurück zum Zitat van Vierzen PB, Massuger LF, Ruys SH, Barentsz JO. Borderline ovarian malignancy: ultrasound and fast dynamic MR findings. Eur J Radiol. 1998;28:136–42.PubMedCrossRef van Vierzen PB, Massuger LF, Ruys SH, Barentsz JO. Borderline ovarian malignancy: ultrasound and fast dynamic MR findings. Eur J Radiol. 1998;28:136–42.PubMedCrossRef
16.
Zurück zum Zitat Warburg OPK, Negelein E. Uber den stoffwechsel der carcinommzelle. Biochem Zeitschrift. 1924;152:309–35. Warburg OPK, Negelein E. Uber den stoffwechsel der carcinommzelle. Biochem Zeitschrift. 1924;152:309–35.
17.
Zurück zum Zitat Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926–32.PubMedCrossRef Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926–32.PubMedCrossRef
18.
Zurück zum Zitat Chung HH, Kwon HW, Kang KW, Kim JW, Park NH, Song YS, et al. Preoperative [18F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol. 2012;23:28–34.PubMedCrossRef Chung HH, Kwon HW, Kang KW, Kim JW, Park NH, Song YS, et al. Preoperative [18F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol. 2012;23:28–34.PubMedCrossRef
19.
Zurück zum Zitat Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics. 2002;22:1305–25.PubMedCrossRef Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics. 2002;22:1305–25.PubMedCrossRef
20.
Zurück zum Zitat Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.PubMedCrossRef Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.PubMedCrossRef
21.
Zurück zum Zitat Kim BS, Kim IJ, Kim S, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med Mol Imaging. 2011;45:36–42.CrossRef Kim BS, Kim IJ, Kim S, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med Mol Imaging. 2011;45:36–42.CrossRef
22.
Zurück zum Zitat Kim SK, Kang KW, Rho JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005;32:757–63.PubMedCrossRef Kim SK, Kang KW, Rho JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005;32:757–63.PubMedCrossRef
23.
Zurück zum Zitat Zhu Z, Wang B, Cheng W, Cheng X, Cui R, Huo L, et al. Endometrial and ovarian F-18 FDG uptake in serial PET studies and the value of delayed imaging for differentiation. Clin Nucl Med. 2006;31:781–7.PubMedCrossRef Zhu Z, Wang B, Cheng W, Cheng X, Cui R, Huo L, et al. Endometrial and ovarian F-18 FDG uptake in serial PET studies and the value of delayed imaging for differentiation. Clin Nucl Med. 2006;31:781–7.PubMedCrossRef
Metadaten
Titel
Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT
verfasst von
Chulhan Kim
Hyun Hoon Chung
So Won Oh
Keon Wook Kang
June-Key Chung
Dong Soo Lee
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 2/2013
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-013-0197-5

Weitere Artikel der Ausgabe 2/2013

Nuclear Medicine and Molecular Imaging 2/2013 Zur Ausgabe